PharmaBoardroom

Articles

Ipsen’s David Meek: Tasked to Transform

In this Q&A, American-born David Meek, today CEO of Paris-based multinational Ipsen, discusses the drugmaker's bold global expansion and R&D transformation-driven by revamped leadership, a biotech mindset, and promoting external innovation.

Q&A: From Gleevec to CAR-T

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.